Sales of anti-obesity drugs like Mounjaro and Wegovy are seeing a jump due to a surge in popularity, Business Standard ...

Sales of anti-obesity drugs like Mounjaro and Wegovy are seeing a jump due to a surge in popularity, Business Standard ...

The demand for obesity drugs in India is surging as Eli Lilly and Novo Nordisk compete. A Pakistani startup sends prosthetics ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for market share, data from research firm Pharmarack showed on Monday.

The health sector is witnessing notable developments, including the rising demand for obesity drugs in India as Eli Lilly and ...

According to consultancy firm Pharmarack, the share of these firms in domestic pharmaceutical formulations market declined marginally to 14.5% in May 2025 from 14.8% in the year-ago month.

Jessica Jani 3 min read 03 Jul 2025, 03:49 PM IST ...

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s (NYSE:LLY) oral obesity pill, orforglipron. Roche Holdings AG (OTC ...

"The patient number may have actually doubled” in May from April, Pharmarack Vice President Sheetal Sapale told Bloomberg News. The demand is gradually rising and should continue, she said.

In response to rising consumer complaints, India's drug regulator is set to implement new labelling norms for medicines that prioritise readability and help make informed choices ...

Mounjaro, priced between ₹14,000 and ₹17,500 per month, recorded sales of nearly ₹24 crore in its first three months, according to Indian pharma market data compiled by Pharmarack.